Cyclosporine consensus conference: With emphasis on the treatment of psoriasis

被引：125

作者：

Lebwohl, M

Ellis, C

Gottlieb, A

Koo, J

Krueger, G

Linden, K

Shupack, J

Weinstein, G

机构：

[1] Mt Sinai Med Ctr, Mt Sinai Sch Med, Dept Dermatol, New York, NY 10029 USA

[2] Univ Michigan, Med Ctr, Dept Dermatol, Ann Arbor, MI 48109 USA

[3] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Dermatol, Newark, NJ 07103 USA

[4] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA

[5] Univ Utah, Sch Med, Dept Dermatol, Salt Lake City, UT USA

[6] Univ Calif Irvine, Coll Med, Dept Dermatol, Irvine, CA 92717 USA

[7] NYU Med Ctr, Dept Dermatol, New York, NY 10016 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 1998年 / 39卷 / 03期

关键词：

D O I：

10.1016/S0190-9622(98)70325-1

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Cyclosporine has been in worldwide use for 15 years for patients who have undergone transplantation operations and is now being used to control inflammatory reactions in other organs (eg, joints, bowel, and skin). Neoral, a more consistently absorbed form of cyclosporine, has recently been approved by the Food and Drug Administration for the treatment of psoriasis. This report outlines the indications, contraindications, dosage recommendations, monitoring requirements, adverse events, drug interactions, interactions with other psoriasis treatments, and suggestions for cyclosporine's use in rotational therapy.

引用

页码：464 / 475

页数：12

共 72 条

[1]

ATMACA LS, 1994, OPHTHALMIC SURG LAS, V25, P321

[2] The risk of skin cancer in renal transplant recipients in Queensland, Australia [J].